Search

SARS-CoV-2 vaccination has been reported as a potential trigger of autoimmune-mediated skin conditions, including leucocytoclastic vasculitis or cutaneous lupus erythematosus (LE).1 Moreover, postvaccination flares of disease requiring treatment have been reported in up to 11% of patients with rheumatic diseases, especially in systemic LE.2 We herein report a case of clinically amyopathic dermatomyositis (CADM) that occurred after mRNA-based SARS-CoV-2 vaccination with BNT162b2. Onset of amyopathic dermatomyositis following mRNA-based SARS-CoV-2 vaccination Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. [Extracted from the article]

We report a case of subacute cutaneous lupus erythematosus (SCLE) following mRNA vaccination with the Pfizer mRNA vaccine BNT162b2, and summarize the current literature on CLE occurring after COVID-19 vaccination. Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination Evidence is accumulating that COVID-19 vaccines might induce or exacerbate autoimmune rheumatic diseases. [Extracted from the article]

We report a case of subacute cutaneous lupus erythematosus (SCLE) that transitioned into systemic lupus erythematosus (SLE) following AdV-vaccination with AZD1222. These findings indicate a transition of SCLE into SLE, fulfilling the current SLE classification criteria.2 Under tapered glucocorticosteroid therapy with prednisolone 250 mg/day, the skin lesions and systemic symptoms significantly improved within 7 days. Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination. [Extracted from the article]